We interrogate multiple diseases through in-depth single cell RNA-sequencing of longitudinally collected tissue samples from patients undergoing various treatments. Our unique approach allows us to identify molecular mechanisms relevant to human biology and to identify genes that causally contribute to disease. We then rapidly turn these insights into drug discovery efforts aimed at developing therapeutics for biomarker-defined patient populations.
|Therapeutic Area||Current Disease Indication Focus||Clinical Screens||Drug Discovery Focus|
|Autoimmune||Inflammatory Bowel Disease||>5 independent screens across different IBD settings||Interrogating mechanistic subsets of disease and treatment response to identify novel drug targets for polygenic IBD|
|Oncology||Oncology primary and secondary (or acquired) treatment resistance||>5 independent screens across different tumor types||Leveraging tissue, genotype, and mechanism-centric approaches to identify novel drug targets for cancers refractory to current treatments, including checkpoint therapies|
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.